Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS

Brain Research

Volumn 815, Issue 1, 1999, Pages 36-43

  Hauss Wegrzyniak, Beatrice ^a   Willard, Lauren B ^a   Del Soldato, Piero ^b   Pepeu, Giancarlo ^a   Wenk, Gary L ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NicOx SA   (France)

Author keywords

Alzheimer's disease; Brain inflammation; Lipopolysaccharide; Microglia; Nonsteroidal anti inflammatory drug (NSAID); Rat

Indexed keywords

ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; BACTERIUM LIPOPOLYSACCHARIDE; FLURBIPROFEN 4 NITROXYBUTYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; ENCEPHALITIS; HISTOPATHOLOGY; MALE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DENTATE GYRUS; ENCEPHALITIS; ENTORHINAL CORTEX; IMMUNOHISTOCHEMISTRY; LIPOPOLYSACCHARIDES; MALE; MICROGLIA; RATS; RATS, INBRED F344;

EID: 0033514060     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)01081-6     Document Type: Article

References (37)

1. Aisen P.S., Davis K.L. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am. J. Psychiatr. 151:1994;1105-1113.
2. Allison M.C., Howaston A.G., Torrace C.J., Lee F.D., Russel R.I. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N. Engl. J. Med. 327:1992;749-754.
3. Altstiel L., Sperber K. Cytokines in Alzheimer's disease. Prog. Neuropsycho-Pharmacol. Biol. Psychiatr. 15:1991;481-495.
4. Banati R.B., Gehrmann J., Schubert P., Kreutzberg G.W. Cytotoxicity of microglia. Glia. 7:1993;111-118.
5. Bannwarth B., Netter P., Gaucher A., Royer-Morrot M.J., Royer R.J. Diffusion of salicylates into cerebrospinal fluid in adults. Therapie. 41:1986;409-411.
6. Breder C.D., Saper C.B. Expression of inducible cyclooxygenase mRNA in the mouse after systemic administration of bacterial lipopolysaccharide. Brain Res. 713:1996;64-69.
7. Breitner J.C.S. Inflammatory processes and anti-inflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol. Aging. 17:1996;789-794.
8. Burrel R. Immunomodulation by bacterial endotoxin. Crit. Rev. Microbiol. 17:1990;188-208.
9. Cacabelos R., Alvarez X.A., Fernandez-Novoa L., Franco A., Mangues R., Pellicer A., Nishimura T. Brain interleukin-1 beta in Alzheimer's disease and vascular dementia. Meth. Find. Exp. Clin. Pharmacol. 16:1994;141-145.
10. Chiang C.-S., Stalder A., Samimi A., Campbell I.L. Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. Dev. Neurosci. 16:1994;212-221.
11. Das S., Potter H. Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron. 14:1995;447-456.
12. Eikelenboom P., Hack C.E., Rozemuller J.M., Stam F.C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. B. Cell. Pathol. 56:1989;259-262.
13. Elmquist J.K., Breder C.D., Sherin J.E., Scammell T.E., Hickey W.F., Dewitt D., Saper C.B. Intravenous lipopolysaccharide induces cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages. J. Comp. Neurol. 381:1997;119-129.
14. Greenblatt D.J., Arendt R.M., Locniskar A. Ibuprofen pharmacokinetics: use of liquid chromatography with radial compression separation. Arzneimittel-Forschung. 33:1983;1671-1673.
15. Griffin W.S.T., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 86:1989;7611-7615.
16. Hauss-Wegrzyniak B., Dobranski P., Stoehr J.D., Wenk G.L. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res. 780:1998;294-303.
17. Hauss-Wegrzyniak B., Lukovic L., Bigaud M., Stoeckel M.E. Brain inflammatory response induced by intracerebroventricular infusion of lipopolysaccharide: an immunohistochemical study. Brain Res. 794:1998;211-224.
18. Jenkinson M.L., Bliss M.R., Brain A.T., Scott D.L. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br. J. Rheumatol. 28:1989;86-88.
19. Kitagawa H., Takeda F., Kohei H. Effect of endothelium-derived relaxing factor on the gastric lesion induced by HCl in rats. J. Pharmacol. Exp. Therap. 253:1990;1133-1137.
20. MacNaughton W.K., Cirino G., Wallace J.L. Endothelium-derived releasing factor (nitric oxide) has protective actions in the stomach. Life Sci. 45:1989;1869-1876.
21. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:1989;341-346.
22. McGeer P.L., Itagaki S., Tago H., McGeer E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79:1988;195-200.
23. McGeer P.L., McGeer E., Rogers J., Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet. 335:1990;1037.
24. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer's disease and other neurodegenerative diseases. Brain Res. Rev. 21:1995;195-218.
25. Mrak R.E., Sheng J.G., Griffin W.S.T. Glial cytokines in Alzheimer's disease. Review and pathogenic implications. Human Pathol. 26:1995;816-823.
26. Myllykangas-Luosujarvi R., Isomaki H. Alzheimer's disease and rheumatoid arthritis. Br. J. Rheumatol. 33:1994;501-502.
27. Rogers J. Inflammation as a pathogenic mechanism in Alzheimer's disease. Drug Res. 45:1995;439-442.
28. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P., Kogan F. Clinical trials of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
29. Rogers J., Scott W., Lue L-F., Brachova L., Civin W.H., Emmerling M., Shivers B., Walker D., McGeer P.L. Inflammation and Alzheimer's disease pathogenesis. Neurobiol. Aging. 17:1996;681-686.
30. Roth S.H. Nonsteroidal anti-inflammatory drugs: gastropathy, deaths and medical practice. Ann. Intern. Med. 109:1988;353-354.
31. Santini G., Sciulli M.G., Padovano R., di Giamberardino M., Rotondo M.T., Del Soldato P., Patrignani P. Effects of flurbiprofen and flurbinitroxybutylester on prostaglandin endoperoxidase synthases. Eur. J. Pharmacol. 316:1996;65-72.
32. Sheng J.G., Ito K., Skinner R.D., Mrak R.E., Rovnaghi C.R., Van Eldik L.J., Griffin W.S.T. In vivo and In vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer's disease. Neurobiol. Aging. 17:1996;761-766.
33. Strauss S., Bauer J., Ganter U., Jonas U., Berger M., Volk B. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in the cortex and hippocampus of Alzheimer's disease patients. Lab. Invest. 66:1992;223-230.
34. Vandenabeele P., Fiers W. Is amyloidosis during Alzheimer's disease due to an IL-1/IL-6-mediated 'acute phase response' in the brain? Immunol. Today. 12:1991;217-219.
35. Wallace J.L., Granger D.N. The pathogenesis of NSAID-gastropathy - are neutrophils the culprits? Trends Pharmacol. Sci. 13:1992;129-131.
36. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M.B., Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat. Gastroenterology. 107:1994;173-179.
37. Paxinos, Watson, 1986.